The Effectiveness and Value of Patisiran and Inotersen for Hereditary Transthyretin Amyloidosis

Kristin Mickle, Karen E. Lasser, Jeffrey S Hoch, Lauren E. Cipriano, William B. Dreitlein, Steven D. Pearson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

DISCLOSURES: Funding for this summary was contributed by the Laura and John Arnold Foundation, Blue Shield of California, and California Health Care Foundation to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from Aetna, AHIP, Anthem, Blue Shield of California, CVS Caremark, Express Scripts, Harvard Pilgrim Health Care, Cambia Health Solutions, United Healthcare, Kaiser Permanente, Premera Blue Cross, AstraZeneca, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck, National Pharmaceutical Council, Prime Therapeutics, Sanofi, Spark Therapeutics, Health Care Service Corporation, Editas, Alnylam, Regeneron, Mallinkrodt, Biogen, HealthPartners, and Novartis. Mickle, Dreitlein, and Pearson are ICER employees. Lasser, Cipriano, and Hoch have nothing to disclose.

Original languageEnglish (US)
Pages (from-to)10-15
Number of pages6
JournalJournal of managed care & specialty pharmacy
Volume25
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Familial Amyloidosis
Prealbumin
Health care
Blue Cross Blue Shield Insurance Plans
Delivery of Health Care
Economics
Electric sparks
Health
Health Services
Personnel
patisiran
Amyloidosis, Hereditary, Transthyretin-Related
Organizations
Pharmaceutical Preparations
Industry
Therapeutics

ASJC Scopus subject areas

  • Pharmacy
  • Pharmaceutical Science
  • Health Policy

Cite this

The Effectiveness and Value of Patisiran and Inotersen for Hereditary Transthyretin Amyloidosis. / Mickle, Kristin; Lasser, Karen E.; Hoch, Jeffrey S; Cipriano, Lauren E.; Dreitlein, William B.; Pearson, Steven D.

In: Journal of managed care & specialty pharmacy, Vol. 25, No. 1, 01.01.2019, p. 10-15.

Research output: Contribution to journalArticle

Mickle, Kristin ; Lasser, Karen E. ; Hoch, Jeffrey S ; Cipriano, Lauren E. ; Dreitlein, William B. ; Pearson, Steven D. / The Effectiveness and Value of Patisiran and Inotersen for Hereditary Transthyretin Amyloidosis. In: Journal of managed care & specialty pharmacy. 2019 ; Vol. 25, No. 1. pp. 10-15.
@article{02eceb334b1946d282ecd8a034802d9e,
title = "The Effectiveness and Value of Patisiran and Inotersen for Hereditary Transthyretin Amyloidosis",
abstract = "DISCLOSURES: Funding for this summary was contributed by the Laura and John Arnold Foundation, Blue Shield of California, and California Health Care Foundation to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from Aetna, AHIP, Anthem, Blue Shield of California, CVS Caremark, Express Scripts, Harvard Pilgrim Health Care, Cambia Health Solutions, United Healthcare, Kaiser Permanente, Premera Blue Cross, AstraZeneca, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck, National Pharmaceutical Council, Prime Therapeutics, Sanofi, Spark Therapeutics, Health Care Service Corporation, Editas, Alnylam, Regeneron, Mallinkrodt, Biogen, HealthPartners, and Novartis. Mickle, Dreitlein, and Pearson are ICER employees. Lasser, Cipriano, and Hoch have nothing to disclose.",
author = "Kristin Mickle and Lasser, {Karen E.} and Hoch, {Jeffrey S} and Cipriano, {Lauren E.} and Dreitlein, {William B.} and Pearson, {Steven D.}",
year = "2019",
month = "1",
day = "1",
doi = "10.18553/jmcp.2019.25.1.010",
language = "English (US)",
volume = "25",
pages = "10--15",
journal = "Journal of managed care & specialty pharmacy",
issn = "2376-0540",
publisher = "Academy of Managed Care Pharmacy (AMCP)",
number = "1",

}

TY - JOUR

T1 - The Effectiveness and Value of Patisiran and Inotersen for Hereditary Transthyretin Amyloidosis

AU - Mickle, Kristin

AU - Lasser, Karen E.

AU - Hoch, Jeffrey S

AU - Cipriano, Lauren E.

AU - Dreitlein, William B.

AU - Pearson, Steven D.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - DISCLOSURES: Funding for this summary was contributed by the Laura and John Arnold Foundation, Blue Shield of California, and California Health Care Foundation to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from Aetna, AHIP, Anthem, Blue Shield of California, CVS Caremark, Express Scripts, Harvard Pilgrim Health Care, Cambia Health Solutions, United Healthcare, Kaiser Permanente, Premera Blue Cross, AstraZeneca, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck, National Pharmaceutical Council, Prime Therapeutics, Sanofi, Spark Therapeutics, Health Care Service Corporation, Editas, Alnylam, Regeneron, Mallinkrodt, Biogen, HealthPartners, and Novartis. Mickle, Dreitlein, and Pearson are ICER employees. Lasser, Cipriano, and Hoch have nothing to disclose.

AB - DISCLOSURES: Funding for this summary was contributed by the Laura and John Arnold Foundation, Blue Shield of California, and California Health Care Foundation to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from Aetna, AHIP, Anthem, Blue Shield of California, CVS Caremark, Express Scripts, Harvard Pilgrim Health Care, Cambia Health Solutions, United Healthcare, Kaiser Permanente, Premera Blue Cross, AstraZeneca, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck, National Pharmaceutical Council, Prime Therapeutics, Sanofi, Spark Therapeutics, Health Care Service Corporation, Editas, Alnylam, Regeneron, Mallinkrodt, Biogen, HealthPartners, and Novartis. Mickle, Dreitlein, and Pearson are ICER employees. Lasser, Cipriano, and Hoch have nothing to disclose.

UR - http://www.scopus.com/inward/record.url?scp=85059239565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059239565&partnerID=8YFLogxK

U2 - 10.18553/jmcp.2019.25.1.010

DO - 10.18553/jmcp.2019.25.1.010

M3 - Article

VL - 25

SP - 10

EP - 15

JO - Journal of managed care & specialty pharmacy

JF - Journal of managed care & specialty pharmacy

SN - 2376-0540

IS - 1

ER -